Niacin (Vitamin B3) supplementation in patients with serotonin-producing neuroendocrine tumor

Neuroendocrinology

Volumn 103, Issue 5, 2016, Pages 489-494

  Bouma, Grietje ^a   Van Faassen, Martijn ^a   Kats Ugurlu, Gursah ^a   De Vries, Elisabeth G E ^a   Kema, Ido P ^a   Walenkamp, Annemiek M E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

N1 methylnicotinamide; Neuroendocrine tumor; Niacin; Serotonin; Vitamin B3

Indexed keywords

1 METHYLNICOTINAMIDE; 5 HYDROXYINDOLEACETIC ACID; ANTINEOPLASTIC AGENT; EVEROLIMUS; INTERFERON; MULTIVITAMIN; NICOTINAMIDE; NICOTINIC ACID; RADIOISOTOPE; SEROTONIN; SOMATOSTATIN DERIVATIVE; TRYPTOPHAN; VITAMIN B COMPLEX; N(1)-METHYLNICOTINAMIDE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID DEFICIENCY; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEUROENDOCRINE TUMOR; NICOTINIC ACID DEFICIENCY; PELLAGRA; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; REFERENCE VALUE; RETROSPECTIVE STUDY; TIME TO TREATMENT; TRYPTOPHAN DEFICIENCY; URINE LEVEL; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; METABOLISM; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORAL DRUG ADMINISTRATION; URINE; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NIACINAMIDE; SEROTONIN; TRYPTOPHAN; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 84941255098     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000440621     Document Type: Article

References (26)

1. Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem 1994; 40: 86-95.
2. Le Floc'h N, Otten W, Merlot E. Tryptophan metabolism, from nutrition to potential therapeutic applications. Amino Acids 2011; 41: 1195-1205.
3. Fleischmajer R, Hyman AB. Clinical significance of derangements of tryptophan metabolism. A review of pellagra, carcinoid and H disease. Arch Dermatol 1961; 84: 563-573.
4. Castiello RJ, Lynch PJ. Pellagra and the carcinoid syndrome. Arch Dermatol 1972; 105: 574-577.
5. Bender DA. Biochemistry of tryptophan in health and disease. Mol Aspects Med 1983; 6: 101-197.
6. Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol 2004; 43: 1-5.
7. Brown TM. Pellagra: an old enemy of timeless importance. Psychosomatics 2010; 51: 93-97.
8. Wan P, Moat S, Anstey A. Pellagra: a review with emphasis on photosensitivity. Br J Dermatol 2011; 164: 1188-1200.
9. World Health Organization. Pellagra and its prevention and control in major emergencies. 2000. www.who.int
10. Bell HK, Poston GJ, Vora J, Wilson NJ. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol 2005; 152: 71-75.
11. Reichman O, Sobel JD. Vulvovaginal pellagra and lichen sclerosus complicating carcinoid syndrome. Obstet Gynecol 2009; 113: 543-545.
12. Bax ND, Woods HF, Batchelor A, Jennings M. Clinical manifestations of carcinoid disease. World J Surg 1996; 20: 142-146.
13. Sjoerdsma A, Weissbach H, Terry LL, Udenfriend S. Further observations on patients with malignant carcinoid. Am J Med 1957; 23: 5-15.
14. Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RR. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol 2005; 100: 2307-2314.
15. Jacob RA, Swendseid ME, McKee RW, Fu CS, Clemens RA. Biochemical markers for assessment of niacin status in young men: urinary and blood levels of niacin metabolites. J Nutr 1989; 119: 591-598.
16. Kema IP, Schellings AM, Hoppenbrouwers CJ, Rutgers HM, de Vries EG, Muskiet FA. High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients. Clin Chim Acta 1993; 221: 143-158.
17. Central Committee on Research Involving Human Subjects (Centrale Commissie Mensgebonden Onderzoek www.ccmo.nl.
18. Klaver EI, van Loon HC, Stienstra R, Links TP, Keers JC, Kema IP, Kobold AC, van der Klauw MM, Wolffenbuttel BH. Thyroid hormone status and health-related quality of life in the LifeLines Cohort Study. Thyroid 2013; 23: 1066-1073.
19. Kema IP, Meijer WG, Meiborg G, Ooms B, Willemse PH, de Vries EG. Profiling of tryptophan-related plasma indoles in patients with carcinoid tumors by automated, on-line, solidphase extraction and HPLC with fluorescence detection. Clin Chem 2001; 47: 1811-1820.
20. De Jong WH, Graham KS, de Vries EG, Kema IP. Urinary 5-HIAA measurement using automated on-line solid-phase extraction-highperformance liquid chromatography-Tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 868: 28-33.
21. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010; 31: 194-223.
22. de Jong WH, Smit R, Bakker SJ, de Vries EG, Kema IP. Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-Tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 603-609.
23. Haugland T, Vatn MH, Veenstra M, Wahl AK, Natvig GK. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res 2009; 18: 719-726.
24. Frojd C, Larsson G, Lampic C, von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes 2007; 5: 18.
25. National Comprehensive Cancer Network guidelines for neuroendocrine tumors. Version 2.2014. www.nccn.org
26. European Neuroendocrine Tumor Society guidelines for foregut, midgut and hindgut NETs. www.enets.org